Regardless of substantial progress in medical care, the morbidity fee of diabetic nephropathy (DN) stays excessive in sufferers with diabetes. Proof means that connective tissue progress issue (CTGF) induced podocyte harm could contribute to DN and CTGF inhibition might cut back albuminuria. Nonetheless, thus far the mechanisms concerned within the impact of CTGF on podocyte harm haven’t been totally understood.
The intention of this examine is to analyze the consequences of therapeutic CTGF antibody on glomerular β-catenin expression and podocyte epithelial-mesenchymal transition (EMT) in diabetic mice. C57BL/6J mice had been randomly divided into three teams as the next: the management, DN, and DN handled by CTGF antibody group.
DN was induced by a single intraperitoneal injection of streptozotocin after which CTGF antibody was administrated thrice per week for eight weeks. Urinary albumin excretion, mesangial proliferation and matrix deposition, and β-catenin expression in glomeruli at mRNA and protein degree had been all elevated in DN mice in comparison with that within the management.
In addition to, the event of EMT in podocytes from diabetic mice, demonstrated by the downregulation of nephrin and upregulation of desmin in glomeruli, was detected. Moreover, blocking CTGF by particular antibody lowered albuminuria, prevented the overexpression of CTGF, in addition to β-catenin, in glomeruli and subsequently ameliorated podocyte EMT in DN mice.
In abstract, this examine urged that CTGF antibody protected podocytes in opposition to harm in DN mice by lowering β-catenin overexpression and stopping podocyte EMT, which could present new perception into the mechanism of CTGF inhibition within the therapy of DN. J. Cell.
Anti-connective tissue progress issue (CTGF/CCN2) monoclonal antibody attenuates pores and skin fibrosis in mice fashions of systemic sclerosis.
Angiotensin II (Ang II) was administered for 14 days by subcutaneous osmotic pump to CTGF KO or C57BL/6 J mice. FG-3019 was administered intraperitoneally thrice per week for two weeks. Pores and skin fibrosis was evaluated by histology and hydroxyproline assay.
Immunohistochemistry staining was used for alpha clean muscle actin (αSMA), platelet-derived progress issue receptor β (PDGFRβ), pSmad2, CD45, von Willebrand issue (vWF), and immunofluorescence staining was utilized for procollagen and Fsp1.
Focusing on connective tissue progress issue (CTGF) in acute lymphoblastic leukemia preclinical fashions: anti-CTGF monoclonal antibody attenuates leukemia progress.
Connective tissue progress issue (CTGF/CCN2) is concerned in extracellular matrix manufacturing, tumor cell proliferation, adhesion, migration, and metastasis. Latest research have proven that CTGF expression is elevated in precursor B-acute lymphoblastic leukemia (ALL) and that elevated expression of CTGF is related to inferior consequence in B-ALL.
On this examine, we characterised the practical position and downstream signaling pathways of CTGF in ALL cells. First, we utilized lentiviral shRNA to knockdown CTGF in RS4;11 and REH ALL cells expressing excessive ranges of CTGF mRNA. Silencing of CTGF resulted in important suppression of leukemia cell progress in comparison with management vector, which was related to AKT/mTOR inactivation and elevated ranges of cyclin-dependent kinase inhibitor p27.
CTGF knockdown sensitized ALL cells to vincristine and methotrexate. Remedy with an anti-CTGF monoclonal antibody, FG-3019, considerably extended survival of mice injected with major xenograft B-ALL cells when co-treated with standard chemotherapy (vincristine, L-asparaginase and dexamethasone). Knowledge recommend that CTGF represents a targetable molecular aberration in B-ALL, and blocking CTGF signaling at the side of administration of chemotherapy could characterize a novel therapeutic strategy for ALL sufferers.
Bioscreening of phage show antibody library and expression of a humanized single-chain variable fragment antibody in opposition to human connective tissue progress issue (CTGF/CCN2).
Extreme expression of CTGF (connective tissue progress issue)/CCN2 has been noticed in lots of fibrotic ailments. The inhibition of the CTGF/CCN2 by antibody has been proven to be clinically helpful for the administration of fibrosis. A phage show humanized single-chain Fv antibody library was screened utilizing CTGF/C (CTGF/CCN2 C-terminal area) because the goal. A phage ELISA was carried out after 4 rounds of biopanning, and ten optimistic clones had been additional evaluated by ELISA and had been chosen for DNA sequencing.
The DNA encoding scFv (single-chain variable fragment) containing a full-length variable area fragment of heavy chain and lightweight chain of human immunoglobulin was inserted into pET-32(a)+ vector, and the fusion protein (TrxA-scFv) containing a thrombin cleavage website was expressed primarily in soluble type. The scFv was obtained by purified fusion protein digested with thrombin after which separated from the fusion accomplice TrxA by gel-filtration chromatography.
An immunological assay confirmed that the purified scFv reacted with CTGF/CCN2 in a concentration-dependent method. The results of the cell migration assay demonstrated that the scFv at 100 ng/ml might successfully inhibit the migration of HUVEC (human umbilical-vein endothelial cells) brought on by CTGF/C. The variety of migratory cells was considerably decreased as in contrast with the detrimental management (1062+/-92 versus 3269+/-288, P<0.001) and the inhibition fee was 90.5%.
A novel peptide remoted from phage show peptides library acknowledged by an antibody in opposition to connective tissue progress issue (CTGF).
The intention of this examine was to isolate a peptide binding to an antibody in opposition to CTGF C-terminal area from the peptide library and to judge its immunological and organic actions. A phage show 12-mer peptide library was screened utilizing anti-CTGF/C antibody because the goal. Ten of the optimistic clones had been sequenced after three rounds bio-panning. The DNA encoding peptide ZD521 was cloned and expressed because the fusion protein(TrxA-ZD521).
The specificity of ZD521 to anti-CTGF/C antibody was decided by aggressive inhibition assay. Mice had been immunized with purified fusion protein(TrxA-ZD521) and the anti-peptide or anti-CTGF response of antiserum was additionally examined by enzyme-linked immunoabsorbent assay (ELISA) and Western blot. The inhibition impact of anti-serum on proliferation of kidney mesangial cells was evaluated by MTT.
A peptide ZD521(GEPQTKLFSFPL) that would particularly acknowledge anti-CTGF/C antibody was remoted. No sequence homology was discovered between ZD521 and CTGF/C. The purified TrxA-ZD521 might particularly bind to anti-CTGF/C antibody and block the binding of anti-CTGF/C antibody to CTGF/C and native CTGF(mesangial cell lysate).
 CTGF Antibody |
|||
| 36807 | SAB | 100ul | EUR 319 |
CTGF Antibody |
|||
| 36807-100ul | SAB | 100ul | EUR 302.4 |
CTGF Antibody |
|||
| MBS7127012-005mL | MyBiosource | 0.05mL | EUR 190 |
CTGF Antibody |
|||
| MBS7127012-01mL | MyBiosource | 0.1mL | EUR 270 |
CTGF Antibody |
|||
| MBS7127012-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
 CTGF antibody |
|||
| 70R-CR023 | Fitzgerald | 50 ug | EUR 312 |
|
Description: Affinity purified Rabbit polyclonal CTGF antibody |
|||
CTGF antibody |
|||
| 38476-100ul | SAB | 100ul | EUR 302.4 |
 CTGF Antibody |
|||
| E19-7091 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
CTGF Antibody |
|||
| E036807 | EnoGene | 100μg/100μl | EUR 255 |
|
Description: Available in various conjugation types. |
|||
CTGF Antibody |
|||
| 1-CSB-PA060417 | Cusabio |
|
|
|
Description: A polyclonal antibody against CTGF. Recognizes CTGF from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:5000, WB:1:500-1:2000, IHC:1:25-1:50 |
|||
CTGF Antibody |
|||
| 1-CSB-PA09429A0Rb | Cusabio |
|
|
|
Description: A polyclonal antibody against CTGF. Recognizes CTGF from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200 |
|||
CTGF antibody |
|||
| 70R-12365 | Fitzgerald | 100 ug | EUR 371 |
|
Description: Rabbit polyclonal CTGF antibody |
|||
CTGF Antibody |
|||
| 5553R-100 | Biovision | each | EUR 405.6 |
CTGF Antibody |
|||
| 5553R-30T | Biovision | each | EUR 175.2 |
CTGF Antibody |
|||
| ABD7091 | Lifescience Market | 100 ug | EUR 525.6 |
CTGF Antibody |
|||
| C30882-100ul | Assay Biotech | 100μl | EUR 217 |
|
Description: CTGF Rabbit Polyclonal Antibody |
|||
CTGF Antibody |
|||
| C30882-50ul | Assay Biotech | 50μl | EUR 143.5 |
|
Description: CTGF Rabbit Polyclonal Antibody |
|||
CTGF Antibody |
|||
| C22169-100ul | Assay Biotech | 100μl | EUR 217 |
|
Description: CTGF Rabbit Polyclonal Antibody |
|||
CTGF Antibody |
|||
| C22169-50ul | Assay Biotech | 50μl | EUR 143.5 |
|
Description: CTGF Rabbit Polyclonal Antibody |
|||
CTGF Antibody |
|||
| AF7537 | Affbiotech | 200ul | EUR 540 |
CTGF Antibody |
|||
| AF7537-100ul | Affinity Biosciences | 100ul | EUR 210 |
|
Description: WB,IF/ICC,ELISA(peptide) |
|||
CTGF Antibody |
|||
| AF7537-200ul | Affinity Biosciences | 200ul | EUR 270 |
|
Description: WB,IF/ICC,ELISA(peptide) |
|||
CTGF Antibody |
|||
| AF7537-50ul | Affinity Biosciences | 50ul | EUR 150 |
|
Description: WB,IF/ICC,ELISA(peptide) |
|||
CTGF Antibody |
|||
| DF7091 | Affbiotech | 200ul | EUR 420 |
CTGF Antibody |
|||
| DF7091-100ul | Affinity Biosciences | 100ul | EUR 168 |
|
Description: WB,IHC,ELISA(peptide) |
|||
CTGF Antibody |
|||
| DF7091-200ul | Affinity Biosciences | 200ul | EUR 210 |
|
Description: WB,IHC,ELISA(peptide) |
|||
Furthermore, the antiserum from mice immunized with TrxA-ZD521 might additionally bind to CTGF/C recombinant protein and native CTGF, in addition to considerably inhibit the proliferation of kidney mesangial cells induced by CTGF/C. Subsequently, ZD521 is perhaps a conformational epitope of CTGF which is probably helpful to be developed as a vaccine for prevention and therapy of fibrosis problems.